Prostatype announces the outcome of the exercise of warrants of series TO 1
On 17 February 2022, the exercise period for Prostatype Genomics AB’s (“the Company”) warrant of series TO 1 ended, which was issued in connection with the Company’s issue of units in September 2020. A total of 14,841 warrants of series TO 1 were exercised. Through the warrants of series TO 1, the Company will receive approximately SEK 162 thousand before issue costs.CEO Fredrik Persson comments“We work purposefully to create growth for the Company and we experience a clear demand for the Prostatype® Test System. In addition to the Nordic market, we now have a market presence in Germany,